359 related articles for article (PubMed ID: 26985834)
1. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A
Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834
[TBL] [Abstract][Full Text] [Related]
2. Ranibizumab for myopic choroidal neovascularization.
Ng DSC; Fung NSK; Yip FLT; Lai TYY
Expert Opin Biol Ther; 2020 Dec; 20(12):1385-1393. PubMed ID: 33003962
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
5. The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook.
Munk MR; Rückert R; Zinkernagel M; Ebneter A; Wolf S
Expert Opin Biol Ther; 2016; 16(4):477-87. PubMed ID: 26666589
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.
Lai TY; Luk FO; Lee GK; Lam DS
Eye (Lond); 2012 Jul; 26(7):1004-11. PubMed ID: 22595908
[TBL] [Abstract][Full Text] [Related]
7. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
Fauser S; Muether PS
Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
[TBL] [Abstract][Full Text] [Related]
9. Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application.
Zhang Y; Han Q; Ru Y; Bo Q; Wei RH
Drug Des Devel Ther; 2015; 9():3413-21. PubMed ID: 26170626
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis.
Wang E; Chen Y
Retina; 2013; 33(7):1375-92. PubMed ID: 23514793
[TBL] [Abstract][Full Text] [Related]
11. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.
Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T
Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of Myopic Choroidal Neovascularization.
Isildak H; Schwartz SG; Flynn HW
Curr Pharm Des; 2018; 24(41):4853-4859. PubMed ID: 30674251
[TBL] [Abstract][Full Text] [Related]
14. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization.
Ng DSC; Ho M; Iu LPL; Lai TYY
Expert Opin Drug Saf; 2022 Jan; 21(1):43-54. PubMed ID: 34228553
[TBL] [Abstract][Full Text] [Related]
15. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
16. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
[TBL] [Abstract][Full Text] [Related]
17. Anti-vascular endothelial growth factor for myopic choroidal neovascularization.
Ng DS; Kwok AK; Chan CW
Clin Exp Ophthalmol; 2012; 40(1):e98-e110. PubMed ID: 21902785
[TBL] [Abstract][Full Text] [Related]
18. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
Kung YH; Wu TT; Huang YH
Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911
[TBL] [Abstract][Full Text] [Related]
19. Differences between pathologic and non-pathologic high myopia in 4-year outcomes of anti-VEGF therapy for macular neovascularization.
Honda Y; Miyata M; Miyake M; Hata M; Numa S; Mori Y; Ooto S; Tamura H; Ueda-Arakawa N; Muraoka Y; Takahashi A; Sado K; Kido A; Tsujikawa A
Sci Rep; 2024 Jun; 14(1):13399. PubMed ID: 38862630
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab.
Ladaique M; Dirani A; Ambresin A
Klin Monbl Augenheilkd; 2015 Apr; 232(4):542-7. PubMed ID: 25902117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
